The Lubrizol Corporation’s LifeSciences, the contract development and manufacturing organisation (CDMO) for complex drug products, is adding commercial drug product manufacturing capacity at its Particle Sciences facility in Bethlehem, Pennsylvania (USA). The 18,000 square foot capacity will include both sterile and non-sterile space with complete lyophilisation and filling operations. Among other things, the facility will be tailored for nano-milling and other complex processes.
“As part of our plans for continued growth in this market, we have accelerated the commercial expansion plans at Particle Sciences. The work has already begun, and we plan to be operational in early 2017 with some of the capacity already spoken for by clients with whom we are currently developing products,” explained Mark Mitchnick, chief medical officer of LifeSciences and CEO of Particle Sciences.
Particle Sciences has developed special expertise in particulates and drug eluting devices. Over the last several years it has taken multiple products into the clinic on behalf of its clients and has a busy 2016 schedule of clinical trial material production in place.
“While the general contract manufacturing organisation (CMO) industry has gone through considerable consolidation around standard dosage forms, LifeSciences has focused on complex processes such as nano-milling, high pressure homogenisation, extrusion and micro-particle fabrication. We are clearly the leader in these areas with significant technology and infrastructure advantages. This current multi-million-dollar expansion further demonstrates our commitment and fills a gap in the global CMO space,” added Mitchnick.
“As part of our plans for continued growth in this market, we have accelerated the commercial expansion plans at Particle Sciences. The work has already begun, and we plan to be operational in early 2017 with some of the capacity already spoken for by clients with whom we are currently developing products,” explained Mark Mitchnick, chief medical officer of LifeSciences and CEO of Particle Sciences.
Particle Sciences has developed special expertise in particulates and drug eluting devices. Over the last several years it has taken multiple products into the clinic on behalf of its clients and has a busy 2016 schedule of clinical trial material production in place.
“While the general contract manufacturing organisation (CMO) industry has gone through considerable consolidation around standard dosage forms, LifeSciences has focused on complex processes such as nano-milling, high pressure homogenisation, extrusion and micro-particle fabrication. We are clearly the leader in these areas with significant technology and infrastructure advantages. This current multi-million-dollar expansion further demonstrates our commitment and fills a gap in the global CMO space,” added Mitchnick.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%